SCHEMBL1031091

SCHEMBL1031091

CCn1c(CC(=O)O)nc(N2CCOCC2)cc1=O

nearest known ligand 0.66

Predicted protein targets (top 7)

geneUniProtsupporting neighboursconfidence
AKT1 P31749 18/20 0.66
PIK3CD O00329 5/20 0.53
PIK3CB P42338 5/20 0.53
PIK3CA P42336 2/20 0.47
CYP3A4 P08684 2/20 0.47
PIK3CG P48736 2/20 0.47
GAA P10253 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12955934 0.86 AKT1 (0.78) AKT1PIK3CDPIK3CBPIK3CACYP3A4
SCHEMBL1031205 0.85 AKT1 (0.72) AKT1PIK3CDPIK3CBPIK3CACYP3A4
SCHEMBL1030876 0.80 AKT1 (1.00) AKT1PIK3CDPIK3CBPIK3CACYP3A4
SCHEMBL12475907 0.79 AKT1 (0.60) AKT1PIK3CDPIK3CBPIK3CACYP3A4
SCHEMBL12475898 0.78 AKT1 (0.70) AKT1PIK3CDPIK3CBPIK3CACYP3A4
SCHEMBL12475860 0.76 AKT1 (0.59) AKT1PIK3CDPIK3CBPIK3CACYP3A4
SCHEMBL12476025 0.72 AKT1 (1.00) AKT1PIK3CDPIK3CBPIK3CACYP3A4
SCHEMBL15500965 0.72 PKM (0.45) AKT1PIK3CDPIK3CBPIK3CACYP3A4
SCHEMBL12475841 0.71 CYP2C19 (0.50) AKT1PIK3CDPIK3CBPIK3CACYP3A4
SCHEMBL932008 0.70 AKT1 (0.70) AKT1PIK3CDPIK3CBPIK3CACYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8993565-B2 (6-oxo-1,6-dihydropyrimidin-2-yl)amide derivatives, preparation thereof and pharmaceutical use thereof as AKT(PKB) phosphorylation inhibitors SANOFI (FR) 2015-03-31 US disclosed
US-20140303156-A1 NOVEL (6-OXO-1,6-DIHYDROPYRIMIDIN-2-YL)AMIDE DERIVATIVES, PREPARATION THEREOF AND PHARMACEUTICAL USE THEREOF AS AKT(PKB) PHOSPHORYLATION INHIBITORS SANOFI SA (FR) 2014-10-09 US disclosed
US-8791255-B2 (6-oxo-1,6-dihydropyrimidin-2-yl)amide derivatives, preparation thereof and pharmaceutical use thereof as AKT(PKB) phosphorylation inhibitors SANOFI (FR) 2014-07-29 US disclosed
EP-2448927-B1 NOVEL (6-OXO-1, 6-DIHYDRO-PYRIMIDIN-2-YL)-AMIDE DERIVATIVES, PREPARATION THEREOF, AND PHARMACEUTICAL USE THEREOF AS AKT PHOSPHORYLATION INHIBITORS SANOFI SA (FR) 2014-03-12 EP disclosed
US-20120270867-A1 NOVEL (6-OXO-1,6-DIHYDROPYRIMIDIN-2-YL)AMIDE DERIVATIVES, PREPARATION THEREOF AND PHARMACEUTICAL USE THEREOF AS AKT(PKB) PHOSPHORYLATION INHIBITORS SANOFI (FR) 2012-10-25 US disclosed
EP-2448927-A1 NOVEL (6-OXO-1, 6-DIHYDRO-PYRIMIDIN-2-YL)-AMIDE DERIVATIVES, PREPARATION THEREOF, AND PHARMACEUTICAL USE THEREOF AS AKT(PKB) PHOSPHORYLATION INHIBITORS SANOFI (FR) 2012-05-09 EP disclosed
WO-2011001114-A1 NOVEL (6-OXO-1, 6-DIHYDRO-PYRIMIDIN-2-YL)-AMIDE DERIVATIVES, PREPARATION THEREOF, AND PHARMACEUTICAL USE THEREOF AS AKT(PKB) PHOSPHORYLATION INHIBITORS SANOFI-AVENTIS (FR) 2011-01-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120270867-A1 NOVEL (6-OXO-1,6-DIHYDROPYRIMIDIN-2-YL)AMIDE DERIVATIVES, PREPARATION THEREOF AND PHARMACEUTICAL USE THEREOF AS AKT(PKB) PHOSPHORYLATION INHIBITORS AKT1, AKT2, MTOR AKT1 1/4885PIK3CD 12/4885PIK3CB 46/4885
US-20140303156-A1 NOVEL (6-OXO-1,6-DIHYDROPYRIMIDIN-2-YL)AMIDE DERIVATIVES, PREPARATION THEREOF AND PHARMACEUTICAL USE THEREOF AS AKT(PKB) PHOSPHORYLATION INHIBITORS AKT1, AKT2, MTOR AKT1 1/4885PIK3CD 12/4885PIK3CB 46/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.